Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic diseases and tissue remodeling. Fibrosis is a key component of multiple diseases affecting all tissues and organ systems and is a leading cause of morbidity and mortality for millions of people worldwide. Promedior has developed a novel platform to treat fibrotic diseases which focuses on targeting the specific monocyte and macrophage cell populations that orchestrate fibrosis and tissue remodeling. This new paradigm for treating fibrotic diseases is upstream and dominant to traditional approaches and takes advantage of universal biology common to all tissues to promote healing without scarring. Promedior has raised $29 million to date and is backed by leading institutional healthcare investors including Morgenthaler Ventures, Polaris Venture Partners, Healthcare Ventures and Easton Capital.
